Merck Group
Portfolio Analysis
A comprehensive BCG growth-share matrix analysis of Merck Group’s three business sectors — Life Science, Healthcare, and Electronics — evaluating competitive positions and strategic resource allocation.
Revenue at a Glance
EINBLICKS · Competitive Intelligence Report
Merck Group · Science & Technology Company · Fiscal Year 2025
Executive Summary
Company Overview
Merck Group, a global science and technology company, operates three principal business sectors — Life Science, Healthcare, and Electronics — working in concert to create value for customers and patients worldwide. This portfolio analysis assists managers in allocating corporate resources across these multiple businesses, classifying and reviewing current and prospective activities as portfolios of investment opportunities. It evaluates each business’s competitive strength alongside the attractiveness of the markets it serves, providing a disciplined framework for strategic decision-making.
Life Science
€ 8,980MLeading provider of products, solutions and services for academic, research, diagnostic, biotech and pharmaceutical customers.
Healthcare
€ 8,607MOncology, rare diseases, neurology & immunology, fertility, and cardiovascular & metabolic disorders.
Electronics
€ 3,515MIntegral part of the semiconductor ecosystem, combining advanced materials with precision delivery and process control technologies.
Sector Analysis
Business Sectors Deep Dive
Life Science Sector
The Life Science sector is a leading provider of products, solutions and services for a wide range of customers, including academic, research and diagnostic labs, biotech and pharmaceutical companies, as well as the industrial sector.
Process Solutions
Supports biotech and pharma customers with filtration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing. Revenue: €3,785M (▲10.7%)
Science & Lab Solutions
Broad portfolio of reagents, consumables, instruments, software and services for research, production and testing across biotech, pharma, public authorities and industrial markets. Revenue: €4,536M (▲0.3%)
Life Science Services
Supports drug development and manufactures novel modalities including high-potency APIs, ADCs and viral & gene therapy products for biotech and pharmaceutical customers. Revenue: €659M (▼4.5%)
Healthcare Sector
The Healthcare business sector helps to create, improve and prolong lives across five therapeutic areas: Oncology, Rare Diseases, Neurology & Immunology, Fertility, and Cardiovascular, Metabolic & Endocrinological Disorders.
Oncology
€1,926M (▲0.3%)
Rare Diseases
€188M
Neurology & Immunology
€1,659M (▲1.9%)
Fertility
€1,457M (▲0.4%)
Cardiovascular, Metabolic & Endocrinological Disorders
€3,050M (▲7.3%)
Electronics Sector
The Electronics sector is an integral part of the semiconductor ecosystem, enabling high yields, reliability and scaling in semiconductor manufacturing by combining advanced materials with precision delivery systems and process control technologies — including metrology and inspection — that directly influence defectivity, uniformity and process stability.
Semiconductor Solutions
Largest BU within the Electronics sector. Offers products and services for semiconductor manufacturing, developing materials for the next generation of components. Revenue: €2,494M (▼1.4%)
Optronics Business
Delivers solutions for the optoelectronic industry through display materials, optical technologies, metrology and inspection. Revenue: €772M (▲0.6%)
Surface Solutions DIVESTED
Divested to Global New Material International Holdings Ltd., Cayman Islands. Transaction closed July 31, 2025. Revenue: €249M (▲1.9%)
Strategic Framework
BCG Growth-Share Matrix Analysis
The BCG Growth-Share Matrix, developed by the Boston Consulting Group, analyzes the impact of investing resources in different businesses on the corporation’s future earnings and cash flows. Each business is positioned within a matrix based on market growth rate (a proxy for industry maturity and attractiveness) and relative market share (a proxy for competitive strength). The framework assumes that firms must generate cash from mature-market leaders to fund investment in attractive future opportunities.
Stars
The Process Solutions business unit within the Life Science sector is the star. As market leader in a high-growth industry, it is critical to the continued success of the firm. As the industry matures, it will transition to the lower-left quadrant and become a cash cow. In the short run, Process Solutions is often a net user of cash, requiring continued investment to maintain leadership.
Question Marks
Life Science Services and Healthcare’s Rare Diseases and Cardiovascular, Metabolic & Endocrinological Disorders businesses operate in high-growth industries with low relative market shares. These require large cash infusions — for both expansion and marketing — to build share. Successful management transforms them into Stars; failure allows them to become Dogs as their markets mature.
Cash Cows
The Fertility Therapeutic Business holds a high relative share of low-growth markets. It is the primary generator of profits and cash in the corporation, requiring little additional capital investment. Its stable market and scale leadership yield economies of scale and high profit margins. The corporation relies on Fertility cash flows to support Question Marks and Stars — and to protect the portfolio’s overall stability and earnings.
Dogs
The Electronics sector (Semiconductor Solutions, Optronics, Surface Solutions) along with Science & Lab Solutions, Neurology & Immunology and Oncology are low-share businesses in low-growth markets. While they may generate some cash, they typically yield low profits or losses. Divestiture is a key option — the Surface Solutions business was already divested to Global New Material International Holdings Ltd. on July 31, 2025.
Strategic Implications
Conclusion & Resource Allocation Strategy
Strategic Imperatives for Merck Group
🐄 Cash Cow — Defend & Harvest
The Fertility Therapeutic Business is the primary generator of profits and cash. It is the habitual source of stability, offsetting fluctuations elsewhere in the portfolio. Its performance has significant impact on the overall parent in terms of stability, earnings, cash flow and costs — it will be protected vigorously.
⭐ Star — Invest & Grow
Process Solutions is the most promising area for resource investment and market position building. While a net user of cash in the short run, its high-growth trajectory makes it the foundation of Merck’s future earnings. This position was reinforced with expansion of the filter manufacturing facility in Blarney Business Park, Cork, Ireland (September 2025) and the planned acquisition of JSR Corporation’s chromatography business in Japan.
❓ Question Marks — Selectively Build
Life Science Services, Rare Diseases and Cardiovascular, Metabolic & Endocrinological Disorders require targeted investment to build market share. If management successfully increases share, these businesses become Stars. They represent offensive strategic moves to build future portfolio strength alongside the current Stars.
🐕 Dogs — Harvest or Divest
The Electronics sector businesses (Semiconductor Solutions, Optronics) and the identified Healthcare and Life Science Dogs are candidates for harvest or divestment. The Surface Solutions business unit has already been divested, demonstrating disciplined portfolio management and freeing capital for higher-return opportunities.
Key Investment Actions — FY2025
Invested ~€150 million to expand filter manufacturing in Blarney Business Park, Cork, Ireland (September 2025) — supporting the Process Solutions Star. Acquiring JSR Corporation’s chromatography business (Japan) to expand downstream processing portfolio. Surface Solutions divested to Global New Material International Holdings Ltd., Cayman Islands (closed July 31, 2025).